Core Viewpoint - The National Advertising Division (NAD) is referring BridgeBio Pharma Inc. to government agencies for failing to participate in an inquiry regarding advertising claims about its product Attruby compared to Pfizer's Vyndamax [1][3]. Group 1: Company Actions - BridgeBio Pharma Inc. declined to engage in the NAD self-regulatory process, leading to the referral to appropriate government agencies [3]. - Pfizer, Inc. challenged claims made by BridgeBio regarding the superiority of Attruby over Vyndamax, citing misleading information based on FDA correspondence [2]. Group 2: Product Information - Both Pfizer and BridgeBio market prescription medications for treating transthyretin amyloid cardiomyopathy, a serious condition caused by the accumulation of transthyretin protein in the heart and other organs [2]. - The specific claims under scrutiny involve the assertion that Attruby offers greater TTR stabilization rates compared to Vyndamax [2]. Group 3: Regulatory Context - The NAD operates as part of BBB National Programs, which focuses on independent self-regulation and dispute resolution in advertising, ensuring truthfulness and fair competition [5]. - BBB National Programs has been enhancing consumer trust in business for over 50 years through various self-regulatory initiatives [4].

As filed with the U.S. Securities and Exchange Commission on February 6, 2024. Registration No. 333-276591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ HELIX ACQUISITION CORP. II (Exact name of registrant as specified in its charter) ____________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdicti ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2024. Registration No. 333-276591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ HELIX ACQUISITION CORP. II (Exact name of registrant as specified in its charter) ____________________________ | Cayman Islands 6770 | N/A | | --- | --- | | (State or other jurisdiction of (P ...

As filed with the U.S. Securities and Exchange Commission on January 18, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ HELIX ACQUISITION CORP. II (Exact name of registrant as specified in its charter) ____________________________ (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 N/A (Primary Standard ...